Verona Pharma’s Post

Heparin Induced Thrombocytopenia Market to witness surge, Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma companies are expected to change the Heparin-induced Thrombocytopenia Market scenario by 2032, forecasts DelveI https://lnkd.in/guTzZfc2 #marketanalysis #marketresearch #marketresearchreports #businessintelligence

I’d highly recommend tuning in to the below panel discussion. Definitely some interesting topics!

IgA Nephropathy Market to Exhibit Rapid Growth Rate | Chinook Therapeutics, RemeGen, Novartis, Ionis Pharma, Vera Therapeutics, Eledon Pharma, Guangdong Hengrui Pharma, companies are expected to change the IgA Nephropathy Market scenario by 2032, forecas https://lnkd.in/g_U6Fv3a #marketanalysis #marketresearch #marketresearchreports #businessintelligence

So proud to let you know of a chance for research teams from any discipline to win monetary awards/travel grants for efforts to find new insights from AMR surveillance data. Vivli has launched the 2024 Vivli AMR Surveillance Data Challenge, funded by GARDP, Paratek, Pfizer and Vivli. This is Vivli’s 2nd AMR data challenge, which aims to stimulate and support the innovative re-use of surveillance data available in the AMR Register.   What prizes can be won?   There are six monetary awards/travel grants: A Grand Prize Award - $10,000 and a travel grant of $5,000 to travel to ESCMID Global or ASM Microbe in 2025, if their abstract is accepted 4 awards - Each receiving $5,000 and a travel grant of $2,500 to travel to ESCMID Global or ASM Microbe in 2025, if their abstract is accepted - 2 in Innovation and 2 in Impact  1 AMR Student Innovation Award – a travel grant of $5,000 to travel to ESCMID Global or ASM Microbe in 2025, if their abstract is accepted. Teams must indicate that they are entering for this award up front, as the entries will be judged separately.   How to participate? See below  

BioPharmCatalyst currently has 56 upcoming events within the PDUFA, PDUFA Priority Review, and/or Advisory Committee categories over the next several years. Check out our PDUFA calendar to stay on top of all of these major regulatory decisions. #biotech #biotechinvesting #fdacalendar #regulatory #biotechstocks #pharmainvesting #pdufa #catalyst #betherewhenithappens #fasterscience

If you missed the WPC here’s your chance to see s bit of what went on and the latest science

One of my connections, Robert Geiger , is participating in this discussion panel at the ChemOutsourcing show in 2024! If you're in the life sciences and going to be in the area, might as well stop by. Should be an insightful discussion!

ChemOutsourcing, which takes place in September, features a panel discussion on sourcing GLP-1-based therapeutics. That is 3 months from now. Will the shortages of incretin-based therapeutics be a thing of the past by then? I doubt it. Will we see any hints of change in manufacturing strategies to tackle the enormous environmental issues of using standard SPPS technology at multi-metric ton scale? I am skeptical. Will that issue even be discussed? Let us wait and see. The panel discussion should certainly be interesting. It would be great to have environmental chemists and representatives of alternative manufacturing technologies in the audience or on the panel to enliven the session.

https://lnkd.in/e6mJGyHD Novartis is close to clinching an acquisition of Cytokinetics and its promising heart drug, as big pharmaceutical companies continue to snap up fast-growing biotechs to replenish their pipelines. A purchase by the Swiss drug company of South San Francisco-based Cytokinetics, which has a market value of more than $10 billion, could be completed as soon as this week, according to people familiar with the situation. Cytokinetics is focused on so-called muscle activators and inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised, according to its website. Cytokinetics’ #cardiomyopathy therapy would complement drugs like the cholesterol treatment called #Leqvio that Novartis acquired as part of a nearly $10 billion deal for The Medicines Company in 2020. #BigPharma

Ground-breaking Insights: Parkinson’s Disease Market Report Delivers Comprehensive Analysis and Future Projections by DelveInsight |Cerevel Therapeutic, Pfizer, Pharma Two B, AbbVie, Biogen, Denali Therapeutics, Annovis Bio, Amneal Pharmaceutical, BioVie https://lnkd.in/gg3NDC7t #marketanalysis #marketresearch #marketresearchreports #businessintelligence